ArticleJournal of oral biology and craniofacial research
MCM3 and Ki67 proliferation markers in odontogenic cysts and ameloblastoma.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Differences of immunohistochemical profiling of MOC-31, caveolin-1, connexin-43, Ki-67 in ameloblastic fibroma, ameloblastic fibrodentinoma, ameloblastic fibro-odontoma, and odontomas.World journal of experimental medicine · 2026Article
- PCNA and MCM 2 in Odontogenic Tumors: An Immunnohistological Study.Journal of pharmacy & bioallied sciences · 2025Article
- Immunohistochemical Analysis of Dentigerous Cysts and Odontogenic Keratocysts Associated with Impacted Third Molars-A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- Prognostic value of the expression and localization of cell proliferation and apoptosis markers in unicystic ameloblastomas.Scientific reports · 2024Article
- The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort.Frontiers in pharmacology · 2024Article
- Function and Therapeutic Potential of Non-Coding RNA in Ameloblastoma.OncoTargets and therapy · 2024Review
- MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Archiv : an international journal of pathology · 2022Article
- CDC7 Expression in Selected Odontogenic Tumors.International journal of dentistry · 2022Article
- Decompression induces inflammation but do not modify cell proliferation and apoptosis in odontogenic keratocyst.Journal of clinical and experimental dentistry · 2022Article
- Management of an extensive odontogenic keratocyst: A rare case report with 10-year follow-up.Medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMCM3 is a marker of proliferation that has been used as a diagnostic or prognostic marker in many pathologic lesions. PURPOSE: The purpose of this study is to investigate the proliferative activity of dentigerous cysts, odontogenic keratocyst and ameloblastoma using minichromosome maintenance 3 (MCM3) and compare it with Ki-67 proliferation marker.
methodsIn this cross-sectional study, 40 cases including 11 cases of dentigerous cyst, 14 odontogenic keratocyst, and 15 ameloblastoma were included. Immunohistochemical expression of MCM3 and Ki-67 were investigated and compared statistically using ANOVA, Chi-square, Tukey and Spearman's correlation tests.
resultsAll subjects were positive for Ki-67 and MCM3. There was a significant difference in MCM3 and Ki-67 expression among all groups. Compared to Ki-67, MCM3 exhibited a higher level of expression. Ameloblastoma and odontogenic keratocyst revealed higher expression rate of both markers in comparison to dentigerous cysts.
conclusionThe results showed MCM3 and Ki67 expression in the most common odontogenic cysts and tumors, especially more aggressive lesions. MCM3 might have a role in pathogenesis of these lesions and could be a reliable marker for assessing proliferation activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.